ProQR Therapeutics (PRQR) Shares Outstanding (Diluted Average) (2014 - 2025)
ProQR Therapeutics recorded quarterly Shares Outstanding (Diluted Average) of $122.6 million in Q4 2025, up 32775776.02% quarter-over-quarter from $374.1 in Q3 2025, and up 33.29% year-over-year from $92.0 million in Q4 2024.
ProQR Therapeutics' Shares Outstanding (Diluted Average) history runs 12 years deep, the most recent figure standing at $122.6 million for Q4 2025.
- In Q4 2025, Shares Outstanding (Diluted Average) rose 33.29% year-over-year to $122.6 million; the TTM figure through Dec 2025 stood at $122.6 million (up 33.29% YoY), while the FY2025 annual figure was $122.6 million, up 33.29% from the prior year.
- Shares Outstanding (Diluted Average) came in at $122.6 million for Q4 2025 at ProQR Therapeutics, up from $374.1 in the prior quarter.
- In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $122.6 million in Q4 2025 to a low of $97.77 in Q1 2024.
- A 5-year average of $18.7 million and a median of $339.45 in 2023 frame the typical range for Shares Outstanding (Diluted Average).
- Across the five-year window, Shares Outstanding (Diluted Average) soared 6655431.46% in 2022 and plunged 58.01% in 2023, its largest moves.
- ProQR Therapeutics' Shares Outstanding (Diluted Average) stood at $1098.2 in 2021, then jumped by 6655431.46% to $73.1 million in 2022, then rose by 19.25% to $87.2 million in 2023, then increased by 5.54% to $92.0 million in 2024, then surged by 33.29% to $122.6 million in 2025.
- According to Business Quant data, Shares Outstanding (Diluted Average) over the past three periods registered $122.6 million, $374.1, and $237.71 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Diluted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 3.06 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 810.00 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 118.76 Bn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 256.30 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 107.70 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 138.23 Mn |
| 10 | ProQR Therapeutics | 174.11 Mn | 66.54 Mn | - | 122.61 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 122.61 Mn |
| Sep 30, 2025 | 374.10 |
| Jun 30, 2025 | 237.71 |
| Mar 31, 2025 | 105.19 |
| Dec 31, 2024 | 91.99 Mn |
| Sep 30, 2024 | 252.59 |
| Jun 30, 2024 | 140.00 |
| Mar 31, 2024 | 97.77 |
| Dec 31, 2023 | 87.16 Mn |
| Sep 30, 2023 | 304.81 |
| Jun 30, 2023 | 228.67 |
| Mar 31, 2023 | 118.07 |
| Dec 31, 2022 | 73.09 Mn |
| Sep 30, 2022 | 725.96 |
| Jun 30, 2022 | 416.15 |
| Mar 31, 2022 | 224.47 |
| Dec 31, 2021 | 1,098.21 |
| Sep 30, 2021 | 825.50 |
| Jun 30, 2021 | 578.05 |
| Mar 31, 2021 | 301.56 |
| Dec 31, 2020 | 1,108.83 |
| Sep 30, 2020 | 782.61 |
| Jun 30, 2020 | 440.58 |
| Mar 31, 2020 | 353.26 |
| Dec 31, 2019 | 1,527.50 |
| Sep 30, 2019 | 1,090.48 |
| Jun 30, 2019 | 741.60 |
| Mar 31, 2019 | 409.19 |
| Dec 31, 2018 | 1,244.12 |
| Sep 30, 2018 | 860.72 |
| Jun 30, 2018 | 680.26 |
| Mar 31, 2018 | 40,541.58 |
| Dec 31, 2017 | 2,025.18 |
| Sep 30, 2017 | 156,283.41 |
| Jun 30, 2017 | 1,011.59 |
| Mar 31, 2017 | 479.43 |
| Mar 31, 2016 | 25.75 Mn |
| Mar 31, 2015 | 11.30 |
| Mar 31, 2014 | 8.86 Mn |